Skip to main content

Table 2 Tumor response according to RECIST version 1.1 (response-evaluable population)

From: Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma

Response

Patients, n (%)

P a

All patients (N = 64)

Cohort 1 (n = 22)

Cohort 2 (n = 19)

Cohort 3 (n = 23)

CR

0

0

0

0

NA

PR

42 (66)

15 (68)

12 (63)

15 (65)

0.94

SD

15 (23)

5 (23)

4 (21)

6 (26)

0.93

PD

7 (11)

2 (9)

3 (16)

2 (9)

0.72

ORR

42 (66)

15 (68)

12 (63)

15 (65)

0.94

DCR

57 (89)

20 (91)

16 (84)

21 (91)

0.72

  1. Cohort 1, cisplatin 75 mg/m2 day 1 + nab-paclitaxel 260 mg/m2 day 1 Q3W; Cohort 2, cisplatin 75 mg/m2 day 1 + nab-paclitaxel 140 mg/m2 day 1, 8 Q3W; Cohort 3, cisplatin 75 mg/m2 day 1 + nab-paclitaxel 100 mg/m2 day 1, 8, 15 Q3W
  2. a P value for the inter-cohort difference
  3. NA, not applicable; PD, progressive disease
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us